Related by context. All words. (Click for frequent words.) 71 leukemia AML 71 Acute Myeloid Leukemia 71 Kit CD# positive 71 refractory chronic lymphocytic 70 dasatinib Sprycel ® 70 hypereosinophilic syndrome 70 Chronic Myeloid Leukemia 70 chronic eosinophilic leukemia 70 cutaneous T 69 metastatic renal cell carcinoma 69 acute myelogenous leukemia AML 69 Cutaneous T 69 Relapsed Refractory 69 Annamycin 68 leukemia ALL 68 Follicular Lymphoma 68 cutaneous T cell 68 familial amyloidotic polyneuropathy FAP 68 acute myeloid leukemia AML 68 cell lymphoma CTCL 68 Cloretazine 68 Omacetaxine 68 leukemia CLL 67 generation purine nucleoside 67 systemic juvenile idiopathic 67 metastatic castration resistant 67 gastrointestinal stromal tumor GIST 67 CYT# potent vascular disrupting 67 myelofibrosis polycythemia vera 67 myelodysplastic syndromes MDS 67 bevacizumab Avastin ® 67 hormone LHRH antagonist 67 erlotinib Tarceva ® 67 cetuximab Erbitux R 67 Romidepsin 67 Metastatic Colorectal Cancer 67 Chronic Lymphocytic Leukemia 67 TNF Tumor Necrosis Factor 66 PI3K/Akt pathway inhibitor 66 relapsed refractory multiple myeloma 66 Chronic Lymphocytic Leukemia CLL 66 metastatic malignant 66 lintuzumab SGN 66 Advanced Renal Cell 66 relapsed multiple myeloma 66 L Annamycin 66 unresectable recurrent 66 Amrubicin 66 relapsing multiple sclerosis 66 SPRYCEL ® 66 myelodysplastic myeloproliferative diseases 66 Peginterferon alfa 2b 66 myelodysplastic syndrome MDS 66 LymphoStat B belimumab 66 prostate cancer HRPC 66 Soft Tissue Sarcoma 66 chronic lymphocytic leukemia CLL 66 receptor tyrosine kinase inhibitor 66 non splenectomized 66 Myelodysplastic Syndrome MDS 66 gastrointestinal stromal tumors GIST 66 imatinib Gleevec ® 66 FOLOTYN ® 66 PEGylated Fab fragment 66 Evoltra ® 66 tumors GIST 66 Novel Oral 65 systemic lupus erythematosus SLE 65 multiple myeloma MM 65 Myelodysplastic Syndromes 65 purpura ITP 65 metastatic colorectal carcinoma 65 autoantibody positive 65 toenail onychomycosis 65 refractory acute myeloid 65 pediatric acute lymphoblastic 65 metastatic gastric 65 Voreloxin 65 HER2 positive metastatic breast 65 Malignant Melanoma 65 Diffuse Large B 65 Neovascular Age Related Macular 65 Clofarabine 65 Myelofibrosis 65 non metastatic osteosarcoma 65 metastatic castrate resistant 65 lymphoma CTCL 65 unresectable stage 65 Lupus Nephritis 65 Chronic lymphocytic leukemia 65 antibody MAb 65 refractory multiple myeloma 65 refractory cutaneous T 65 alvespimycin 65 pralatrexate injection folate analogue 65 Decitabine 65 sunitinib Sutent ® 65 recurrent NSCLC 65 pan HDAC inhibitor 65 Cloretazine ® 65 Meets Primary Endpoint 65 PNP inhibitor 65 complement inhibitor eculizumab 65 dasatinib Sprycel 65 Philadelphia Chromosome Positive 65 sorafenib tablets 65 atypical hemolytic uremic syndrome 65 unresectable locally advanced 65 Severe Sepsis 65 Metastatic Melanoma 64 Phase IIb Trial 64 relapsed Acute Myeloid 64 indolent follicular non 64 PEGylated anti 64 aggressive systemic mastocytosis 64 immune idiopathic thrombocytopenic 64 refractory NSCLC 64 Hodgkin lymphoma HL 64 Personalized Immunotherapy 64 CD3 monoclonal antibody 64 acute promyelocytic leukemia APL 64 Complicated Skin 64 remission induction 64 Vidaza ® 64 tyrosine kinase inhibitor TKI 64 systemic anaplastic large 64 chronic myeloid 64 sodium thiosulfate STS 64 Initiate Phase 64 severe oral mucositis 64 Trial Evaluating 64 Aplidin R 64 Syndrome LEMS 64 Temsirolimus 64 Previously Treated 64 humanized anti 64 MKC# MT 64 Epratuzumab 64 VEGFR2 inhibitor 64 radiation sensitizer 64 dependent kinase inhibitor 64 biliary tract cancer 64 atypical Hemolytic Uremic Syndrome 64 castrate resistant prostate cancer 64 telomerase therapeutic 64 refractory gout 64 Elagolix 64 lupus nephritis 64 relapsing remitting MS RRMS 64 Advanced Melanoma 64 Study Evaluating 64 Fludarabine 64 Acute Myelogenous Leukemia AML 64 refractory acute promyelocytic 64 resistant hormone refractory 64 Hormone Refractory Prostate Cancer 64 Initiates Phase II 64 IMiDs ® 64 idiopathic thrombocytopenic purpura ITP 64 advanced nonsquamous NSCLC 64 PD LID 64 recurrent glioblastoma multiforme 64 Chronic lymphocytic leukemia CLL 64 Prodarsan R 64 Mantle Cell Lymphoma 64 Hsp# Inhibitor 64 luteinizing hormone releasing 64 relapsed leukemia 64 Fx #A 64 huN# DM1 64 R sorafenib tablets 64 essential thrombocythemia ET 64 pancreatic NET 63 Hodgkin lymphoma NHL 63 rheumatoid arthritis psoriatic arthritis 63 oropharyngeal candidiasis OPC 63 Phase 2b Clinical Trial 63 dyskinesia PD LID 63 Tyrosine Kinase Inhibitor 63 hypoparathyroidism 63 investigational monoclonal antibody 63 metastatic GIST 63 non myeloid malignancies 63 5 fluorouracil leucovorin 63 docetaxel Taxotere R 63 Oral Fingolimod 63 MEK inhibitor 63 TO AVOID PREGNANCY WHILE 63 Randomized Phase 63 modified glutathione analog 63 Glioblastoma Multiforme 63 bortezomib Velcade R 63 CML CP 63 Frozen Shoulder syndrome Adhesive 63 Initiates Clinical Trial 63 keloid scarring 63 Prolongs Survival 63 chronic immune thrombocytopenic 63 VELCADE melphalan 63 precursor acute lymphoblastic 63 Hedgehog Pathway Inhibitor 63 cell carcinoma RCC 63 Adjunctive Therapy 63 Romiplostim 63 Newly Diagnosed Multiple Myeloma 63 orally administered synthetic retinoid 63 Chronic Myelogenous Leukemia 63 relapsing remitting multiple sclerosis 63 YONDELIS 63 Systemic lupus erythematosus SLE 63 Cell Lymphoma 63 immunotherapeutic agent 63 Peginterferon 63 metastatic colorectal 63 Clevudine 63 Daclizumab 63 leukemia APL 63 RANK Ligand inhibitor 63 MT# MEDI 63 Pharmacokinetics PK 63 sodium glucose cotransporter 63 Pivotal Phase 63 Completes Enrollment 63 GW# [003] 63 Previously Untreated 63 Alemtuzumab 63 MPS IVA 63 progressive PsA 63 Systemic Lupus Erythematosus SLE 63 Ph + acute lymphoblastic 63 diagnosed Ph + 63 IgG1 monoclonal antibody 63 Janus kinase 63 acute myeloid 63 Systemic Juvenile Idiopathic 63 Azacitidine 63 Phase #b/#a clinical 63 Lambert Eaton Myasthenic 63 Dacogen injection 63 refractory indolent non 63 ® lenalidomide 63 Vidaza R 63 TELINTRA R 63 stage IIIb IV 63 advanced metastatic renal 63 lymphocytic leukemia 63 galiximab 63 Nexavar tablets 63 thalidomide Thalomid 63 cilengitide 63 imatinib resistant 63 Phase 2b Trial 63 oral nucleoside analogue 63 relapsed MM 63 Polymerase Inhibitor 63 lymphoid malignancies 63 BCR ABL inhibitor 63 Completes Patient Enrollment 63 ara C 63 Cyclooxygenase Inhibiting Nitric Oxide 63 nilotinib Tasigna ® 63 mRCC 63 class anticancer quinolone 63 BENLYSTA ® 63 Randomized Phase II 63 Lenalidomide 63 Gleevec resistant 63 non nucleoside inhibitor 63 Rheumatoid Arthritis RA 63 Adjuvant Treatment 63 docetaxel Taxotere ® 63 dilated cardiomyopathy DCM 63 evaluating picoplatin 62 bevacizumab Avastin R 62 systemic lupus erythematosus 62 rALLy clinical trial 62 alfa 2a 62 acyclovir Lauriad R 62 metastatic hormone refractory 62 AEG# 62 accumulate preferentially 62 PKC# 62 Myelodysplastic Syndromes MDS 62 stage IIIB 62 cell acute lymphoblastic 62 hypophosphatasia 62 Systemic Sclerosis 62 gefitinib Iressa 62 Pivotal Phase III 62 HDAC Inhibitor 62 AVONEX ® 62 irinotecan containing 62 triggers apoptosis programmed 62 Castration Resistant Prostate Cancer 62 Hepatocellular Carcinoma HCC 62 neurogenic orthostatic hypotension 62 idiopathic pulmonary fibrosis IPF 62 Initiated Phase 62 aplastic anemia AA 62 IL# PE#QQR 62 oral proteasome inhibitor 62 Relapsing Remitting Multiple Sclerosis 62 AA Amyloidosis 62 INSPIRE Trial Phase III 62 uremic pruritus 62 Ozarelix 62 sarcoma melanoma 62 Initiates Phase 62 gastrointestinal stromal tumors 62 IAP inhibitor 62 Safinamide 62 5 FU leucovorin 62 6 sulfatase 62 Luteinizing Hormone Releasing Hormone 62 Cerebril TM 62 Phase III Trial 62 novel histone deacetylase 62 IMiDs R 62 peptidic compound 62 orally inhaled migraine 62 cetuximab Erbitux ® 62 registrational trial 62 metastatic renal cell 62 opioid induced constipation OIC 62 depsipeptide 62 Bosutinib 62 vinca alkaloids 62 stage IIIb 62 Nexavar sorafenib 62 alpha folate receptor 62 Atypical Hemolytic Uremic Syndrome 62 active ankylosing spondylitis 62 AA amyloidosis 62 phase IIb clinical 62 oral prodrug 62 Enzyme Replacement Therapy 62 Eculizumab 62 Pivotal Study 62 Fludara ® 62 Plicera 62 Brentuximab Vedotin SGN 62 Aryplase 62 MPS VI 62 TKB# 62 glioblastoma multiforme GBM 62 Relapsed Multiple Myeloma 62 CD# CEA 62 FRDA 62 Metastatic Renal Cell Carcinoma 62 post herpetic neuralgia PHN 62 GATTEX ™ 62 nucleoside analog 62 chronic myeloid leukemia CML 62 patientswith 62 Gaucher Disease 62 Wafer polifeprosan 62 metastatic kidney 62 Patients Treated With 62 relapsed follicular lymphoma 62 R roscovitine CDK cyclin 62 demonstrated antitumor activity 62 PEGylated interferon beta 1a 62 refractory metastatic colorectal cancer 62 CTAP# Capsules 62 Renal Cell Carcinoma 62 Nilotinib 62 castration resistant prostate cancer 62 AVN# Phase 62 MyVax R 62 Tocilizumab 62 MCSP respectively 62 biologic DMARD 62 cell chronic lymphocytic 62 oncolytic virus therapies 62 orally administered inhibitor 62 ALN PCS 62 omacetaxine mepesuccinate 62 refractory AML 62 cisplatin gemcitabine 62 LHRH receptor positive 62 Myelodysplastic Syndrome 62 XL# anticancer compounds 62 non squamous 62 Pralatrexate 62 targeted antifolate 62 Naive Patients 62 novel VDA molecule 62 liposomal formulation 62 Combination REOLYSIN R 62 Bayer HealthCare Onyx Pharmaceuticals 62 pediatric Crohn disease 62 IV NSCLC 62 erlotinib Tarceva R 62 elacytarabine 62 refractory chronic myeloid 62 Vicriviroc 62 Belimumab 62 eosinophilic asthma 62 rheumatoid arthritis RA psoriatic 62 Sapacitabine 62 PRN FDA Approves 62 chronic plaque psoriasis 61 interferon gamma 1b 61 recurrent malignant glioma 61 basal cell carcinoma BCC 61 TORISEL 61 LymphoStat B TM 61 Receives Orphan Drug Designation 61 Ribavirin causes 61 subependymal giant cell 61 Phase III Pivotal 61 humanized interleukin 6 61 Begins Dosing 61 Epidermal Growth Factor Receptor 61 Thiarabine 61 Factor Receptor 61 Aviptadil 61 Phase IIa Clinical Trial 61 decitabine 61 TRACON Pharmaceuticals Inc. 61 diarrhea predominant irritable 61 Degarelix 61 Nexavar ® 61 RAS MAPK pathway 61 histone deacetylase HDAC inhibitor 61 recurrent GBM 61 BENLYSTA TM 61 Humanized Anti 61 assessing T DM1 61 TBC# 61 unique alkylating agent 61 Sprycel dasatinib 61 Tiuxetan 61 AAG geldanamycin analog 61 recurrent glioblastoma multiforme GBM 61 Natalizumab 61 hematological malignancy 61 advanced metastatic prostate 61 virus HCV protease inhibitor 61 targeted radiotherapeutic 61 melphalan prednisone 61 TRACON Pharmaceuticals 61 Malignant Glioma 61 Cyclophosphamide 61 Ovitrelle R Serostim 61 hormone refractory prostate cancer 61 Folfox 61 Refractory Hodgkin Lymphoma 61 Treatment Experienced 61 somatostatin analogue 61 hepatocellular carcinoma HCC 61 Antigen Specific 61 Myelodysplasia 61 Crohn disease CD 61 Gleevec imatinib mesylate 61 Plaque Psoriasis 61 Diabetic Nephropathy 61 including eniluracil ADH 61 sorafenib Nexavar 61 ALN TTR 61 psoriasis rheumatoid arthritis 61 exocrine pancreatic insufficiency EPI 61 Torisel 61 induced macular edema 61 acetonide FA 61 catheter occlusion 61 Granted Orphan Drug 61 Yondelis ® 61 sorafenib Nexavar ® 61 Leukemia AML 61 BARACLUDE ® 61 Ranolazine 61 SinuNase TM 61 Bortezomib 61 unresectable Stage III 61 Ibritumomab Tiuxetan 61 proliferator activated receptor 61 mGluR5 negative 61 polymerase inhibitor 61 oral ghrelin agonist 61 advanced medullary thyroid 61 evaluating tivozanib 61 Albuferon TM 61 trastuzumab DM1 T DM1 61 IMiDs ® compound 61 ELACYT 61 ribavirin Copegus ® 61 Cytarabine Liposome Injection 61 carcinoma mCRC 61 Luramist TM 61 hepatitis C HCV 61 formerly LymphoStat B 61 unresectable liver cancer 61 Predict Response 61 Investigational Treatment 61 TTR amyloidosis 61 Temodar ® 61 nephropathic cystinosis 61 myelofibrosis 61 personalized cellular immunotherapy 61 JAK2 Inhibitor 61 GATTEX ® 61 Soliris eculizumab 61 paroxysmal nocturnal hemoglobinuria PNH 61 follicular lymphoma FL 61 volociximab 61 Clolar ® 61 sapropterin dihydrochloride 61 fistulizing CD 61 huC# DM4 61 essential thrombocythemia 61 Randomized Double Blind 61 AKT inhibitor 61 developing Bicifadine serotonin 61 Tasimelteon 61 Lymphocytic 61 PEGINTRON TM 61 Tyrosine Kinase Inhibitors 61 myeloproliferative disorders 61 protein tyrosine phosphatase 1B 61 Monotherapy 61 Bronchiectasis 61 Phase IIb Clinical Trial 61 Acute Myeloid Leukaemia AML 61 advanced carcinoid 61 non alcoholic steatohepatitis 61 hormone refractory metastatic prostate 61 Ofatumumab 61 Tamibarotene 61 Lennox Gastaut syndrome 61 Phase Ib II 61 esophageal candidiasis 61 secondary hyperparathyroidism 61 paclitaxel Taxol R 61 IMA# 61 recurrent glioblastoma 61 histamine dihydrochloride 61 Phase 2a Clinical Trial 61 Initiates Clinical 61 ATTR PN 61 nonsmall cell lung cancer 61 invasive candidiasis 61 Metastatic Prostate Cancer 61 Glufosfamide 61 poly ADP ribose polymerase 61 metastatic malignant melanoma 61 Pulmonary Arterial Hypertension PAH 61 Chronic Heart Failure 61 Relapsed Refractory Multiple Myeloma 61 TELINTRA 61 Raptiva R 61 Relapsed 61 Etanercept 61 Leukemias 61 primary generalized tonic 61 minimally symptomatic metastatic castrate 61 onset idiopathic hypogonadism 61 Provectus Pharmaceuticals specializes 61 BRIM2 61 Panzem R 61 myeloproliferative diseases 61 kidney urologic 61 follicular non 61 novel emulsion formulation 61 Xyfid TM 61 multicenter Phase III 60 phenylalanine ammonia lyase 60 nucleotide analog 60 1 diabetes T1D 60 follicular NHL 60 primary hypercholesterolemia 60 vidofludimus 60 IAP inhibitors 60 ospemifene 60 Overactive Bladder OAB 60 Ceflatonin R 60 Pirfenidone 60 Archexin 60 methylnaltrexone bromide 60 Onrigin 60 cyclophosphamide methotrexate 60 TEMODAL 60 stable angina pectoris 60 systemic fungal infections 60 transthyretin TTR mediated amyloidosis 60 myocardial infarction ventricular fibrillation 60 GVAX ® 60 Trastuzumab 60 Chronic Hepatitis C 60 symptomatic neurogenic orthostatic hypotension 60 subcutaneous formulation 60 registrational Phase 60 mitogen activated ERK kinase 60 forodesine 60 approved incretin mimetic 60 ORENCIA ® 60 NAGS deficiency 60 Gemzar ® 60 pancreatic neuroendocrine tumors 60 Heterozygous Familial Hypercholesterolemia 60 previously untreated follicular 60 Adalimumab 60 refractory ovarian cancer 60 untreated multiple myeloma 60 Elotuzumab 60 oral dihydropyrimidine dehydrogenase DPD 60 imatinib mesylate 60 Initiates Enrollment 60 PROVENGE ® 60 Sipuleucel T 60 Chronic Myelogenous Leukemia CML 60 Dasatinib 60 Laquinimod 60 MGd 60 including thyroiditis RA 60 brand ciclesonide HFA 60 Troxatyl 60 Phase III Clinical Trial 60 phase Ph + 60 Non Alcoholic Steatohepatitis 60 arthritis PsA 60 BiovaxID TM 60 unresectable 60 Diabetic Macular Edema 60 neuropathic pain metabolic diseases 60 Clinical Trial Results 60 GTC recombinant form 60 delivers fluocinolone acetonide FA 60 2 methoxyestradiol 60 leukemia CML 60 refractory colorectal cancer 60 Idiopathic Pulmonary Fibrosis 60 Alzhemed TM 60 Actemra tocilizumab 60 non porcine pancreatic 60 Gastrointestinal Stromal Tumors 60 Major Depressive Disorder MDD 60 OvaRex ® MAb 60 Evoltra R 60 PSMA ADC 60 CD4 monoclonal antibody 60 relapsed refractory 60 ATTR 60 Silodosin 60 vapreotide acetate 60 mTOR inhibitor 60 plus DOXIL 60 Junovan TM 60 vemurafenib 60 Solazed TM 60 vinca alkaloid 60 EGFR expressing mCRC 60 Juvenile Idiopathic Arthritis 60 Uricase PEG 60 Plus Ribavirin 60 Rituxan rituximab 60 XL# XL# 60 heavily pretreated 60 CLL SLL 60 Allovectin 7 60 topical gel formulation 60 alpha1 antitrypsin deficiency 60 allogeneic bone marrow 60 Treatment Naive 60 Acute myeloid leukemia AML 60 gastrointestinal disorders characterized 60 Recombinant Human 60 Maribavir 60 inflammatory PDE 60 Myeloma Patients 60 Intravenous CP 60 GLOBE NEWSWIRE Cyclacel Pharmaceuticals 60 PDX pralatrexate 60 3 registrational trial 60 CIMZIA ™ 60 dirucotide MBP# 60 Tanespimycin 60 Pyridorin TM 60 Ranibizumab 60 Successfully Completes Phase 60 thetreatment 60 hypoxia activated prodrug 60 metastatic CRC 60 advanced NSCLC 60 juvenile myoclonic epilepsy 60 Relapsed Refractory Aggressive 60 vincristine doxorubicin 60 albiglutide currently 60 vinorelbine tartrate 60 JAK2 V#F 60 oral Janus kinase 60 apoptosis proteins 60 aHUS 60 hypoxia inducible factor 60 BRIM3 60 cancer mCRC 60 Lennox Gastaut Syndrome 60 idiopathic thrombocytopenic purpura 60 HQK 60 biologic therapy 60 Leber Congenital Amaurosis LCA 60 paclitaxel Taxol ® 60 PROSTVAC VF 60 novel topoisomerase 60 Rituximab 60 Apaziquone 60 beta 1a 60 Imatinib mesylate 60 refractory anaplastic astrocytoma 60 Pivotal Trial 60 Enzastaurin 60 Acute Lymphoblastic Leukemia 60 Dapagliflozin 60 imetelstat GRN#L 60 Irinotecan 60 markets Testim ® 60 Acute myeloid leukemia 60 Acute Myelogenous Leukemia 60 CEQ# 60 pertuzumab 60 CABP 60 Blinatumomab 60 Neovascular 60 lintuzumab 60 refractory myeloma 60 metaglidasen 60 serologically active systemic lupus 60 Hepatocellular Carcinoma 60 development peramivir neuraminidase 60 follicular lymphoma 60 Phase 2a Trial 60 soluble tumor necrosis 60 SNT-MC#/idebenone 60 rALLy 60 delta gamma agonist 60 NEBIDO R 60 TRIOLEX ™ 60 metastatic colorectal cancer 60 neurological manifestations 60 Cancer AACR NCI 60 pan histone deacetylase 60 SHPT 60 lenalidomide Revlimid R 60 sunitinib Sutent 60 monoclonal antibody IgG1 Mab 60 CYP#A# CYP#D# 60 erythematosus SLE 60 smoldering myeloma 60 tanespimycin 60 Pegasys ® 60 homozygous familial hypercholesterolemia 60 RoACTEMRA 60 LUX Lung 60 TACI Ig 60 Idiopathic Pulmonary Fibrosis IPF 60 T1DM 60 relapsed acute lymphoblastic 60 Familial Adenomatous Polyposis FAP 60 dextromethorphan quinidine 60 Custirsen 60 bone metastasis 60 investigational humanized monoclonal antibody 60 antiangiogenesis therapies 60 tuberous sclerosis TS 60 pseudobulbar affect PBA 60 AN# topical anti 60 sunitinib malate 60 generation radiolabeled antibody 60 erythematosus 60 relapsed acute myelogenous 60 Therapeutic Vaccine 60 Cell Non Hodgkin 60 partial onset seizures 60 Xanafide 60 ovarian carcinoma 60 clofarabine 60 Pathway Inhibitor 60 BR.# 60 lexidronam injection 60 Mipomersen 60 Aflibercept 60 NASDAQ OPXA 60 methionine aminopeptidase 60 Peginterferon Alfa 2a 60 Multiple Myeloma MM 60 Perifosine KRX 60 refractory Hodgkin lymphoma 60 tiuxetan 60 relapsed ALL 60 DEB# 60 Cetrorelix 60 NSCLC 60 Initiate Clinical Trial 60 TRO# 60 CDK cyclin dependent 60 Cimzia ® certolizumab pegol 60 terlipressin 60 tumor xenograft models 59 metastatic pancreatic 59 autologous cellular immunotherapy 59 Tarceva TM 59 metastatic neuroendocrine tumors 59 prostate cancer CRPC 59 interferon beta 1a infertility 59 gastrin analogue TT 59 ACTEMRA TM 59 pentadentate logo R 59 advanced hepatocellular carcinoma 59 Pooled Analysis 59 Immunotherapeutic 59 gastrointestinal stromal tumor 59 Kinase Inhibitors 59 Pemetrexed 59 medullary thyroid cancer 59 ALN TTR# 59 generation Hsp# inhibitor 59 evaluating mipomersen 59 Vascular Disrupting Agent 59 Ostabolin C TM 59 Severe VOD 59 Therapy Evaluation 59 Fibrillex TM 59 RNAi Therapeutic 59 Tumor Necrosis Factor 59 Aplidin 59 decompensated liver disease 59 peptibody 59 Pertuzumab 59 dacarbazine 59 inhaled liposomal ciprofloxacin 59 use transdermal sumatriptan 59 CIMZIA R 59 chronic opioid 59 Chronic Idiopathic Constipation 59 Bevacizumab 59 INCB# [001] 59 initiated Phase Ib 59 intravesical infusion therapy 59 atherothrombotic events 59 hematologic cancers 59 myeloid metaplasia 59 metastatic carcinoma 59 BCG refractory carcinoma 59 Protease Inhibitor 59 Investigational Oral 59 fallopian tube carcinoma 59 Improves Outcomes 59 ISTODAX ® 59 Azedra 59 Velcade bortezomib 59 vWD 59 receptor inhibiting monoclonal 59 Cloretazine R VNP#M 59 systemic ALCL 59 Pazopanib 59 constipation OIC 59 II Clinical Trial 59 Quinamed 59 small molecule thrombopoietin 59 diabetic nephropathy 59 Proxinium TM 59 Kuvan R 59 Drug Candidate 59 small molecule Hedgehog 59 Certolizumab pegol 59 Biogen Genentech 59 follicular Non Hodgkin 59 adalimumab Humira 59 Relapsing Multiple Sclerosis 59 herpetic keratitis 59 Rhucin ® recombinant 59 Bezielle 59 leukemia lymphoma multiple myeloma 59 antibody MT# 59 Secondary Hyperparathyroidism 59 M2 subunit 59 T#I [002] 59 chronic granulomatous disease 59 cytidine nucleoside analog 59 myeloproliferative neoplasms 59 Vidofludimus 59 undergoing hematopoietic stem 59 Anthracycline 59 relapsed refractory AML 59 tyrosine kinase inhibitors TKIs 59 HRPC 59 Friedreich Ataxia FRDA 59 idarubicin 59 acute leukemias 59 polycythemia vera essential thrombocythemia 59 proteasome inhibitor 59 CD# monoclonal antibody 59 Vidaza azacitidine 59 Node Positive 59 haematologic malignancies 59 Histone Deacetylase 59 recurrent metastatic ovarian cancer 59 orphan medicinal product 59 chronic rheumatic 59 Parathyroid Hormone 59 Presents Preclinical Data 59 Monoclonal Antibody 59 fluoropyrimidine 59 common hematologic malignancy 59 Ceflatonin ® 59 Cancer Cachexia 59 rilonacept 59 erlotinib Tarceva 59 hyaluronidase enzyme 59 EGFR TKI 59 bladder carcinoma 59 baminercept 59 Janus Kinase 59 TASKi2 59 IV melanoma 59 dose escalation clinical 59 HGS ETR1 mapatumumab 59 tamibarotene 59 KRN# 59 pancreatic insufficiency 59 ribavirin RBV 59 pheochromocytoma 59 candidates Azedra TM 59 transplantation HCT 59 LHRH antagonists 59 Kinase Inhibitor 59 non metastatic resectable 59 HuLuc# 59 Noxafil 59 hematologic disorders 59 vaccines oncolytic virus 59 Ecallantide 59 REVLIMID lenalidomide 59 VitiGam 59 KRAS wild 59 metastatic androgen independent 59 cortisol synthesis 59 Phase Ib clinical 59 oncolytic vaccine 59 refractory CTCL 59 Tarceva erlotinib 59 Cytochrome P# 59 alpha antagonist 59 Ceflatonin 59 Cannabinor 59 Copegus ribavirin 59 IMiDs 59 irinotecan doxorubicin oxaliplatin paclitaxel 59 6R BH4 59 Presents Positive 59 Phase Ib IIa 59 gastrointestinal mucositis 59 RhuDex R 59 Achieves Primary Endpoint 59 Atripla combines 59 adecatumumab MT# 59 mertansine 59 Anti VEGF 59 R#/MEM # 59 Vandetanib 59 R rilonacept Injection 59 reslizumab 59 FDA Accepts 59 Epothilone D 59 Files IND 59 targeted immunotherapies 59 non nucleoside HCV 59 pegylated liposomal doxorubicin 59 YONDELIS R 59 Bendamustine 59 haematologic 59 chronic myelogenous leukemia CML 59 myelofibrosis MF 59 FOLFOX6 chemotherapy regimen 59 fistulizing Crohn disease 59 Paraplatin ® 59 IMC A# 59 Bevacizumab Avastin 59 Zorbtive TM 59 Ataluren 59 cystic fibrosis CF 59 Prospective Randomized 59 Amgen Neulasta R 59 Hematological Malignancies 59 Anthrax Toxin 59 acute GvHD 59 eculizumab 59 Tezampanel 59 apoptosis inducer 59 CBLC# 59 pemphigus vulgaris 59 Sym# 59 metastatic bladder 59 pegylated interferon alfa 2a 59 gemcitabine Gemzar ® 59 Crofelemer budesonide foam 59 paroxysmal nocturnal hemoglobinuria 59 renal cell carcinoma 59 dacarbazine DTIC